Meprolen

Omeprazole, the active ingredient in Meprolen, is a proton pump inhibitor presented as an intravenous injection for intravenous use. It is employed to treat gastric and duodenal ulcers, manage gastro‑oesophageal reflux disease, and prevent stress‑related mucosal damage in hospitalized patients.

GNH USA supplies Meprolen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meprolen, a proton pump inhibitor, is used in conditions where suppression of gastric acid is required. - Gastric ulcer: promotes healing by reducing gastric acid secretion. - Duodenal ulcer: accelerates ulcer resolution through acid suppression. - Gastro‑oesophageal reflux disease (GERD): alleviates reflux symptoms by lowering stomach acidity. - Stress‑related mucosal damage: provides prophylaxis against stress ulcers in critically ill patients.

Adverse reactions may occur with any medication. Patients should be monitored for both common and serious events.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: watery stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile infection: persistent diarrhoea with abdominal cramping. - Hypomagnesemia: low serum magnesium levels, potentially causing muscle cramps or arrhythmias. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Bone fracture risk: long‑term use may be associated with decreased bone density. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal impairment: adjust therapy and monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Known hypersensitivity: avoid if patient has previous allergic reaction to omeprazole or other PPIs. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Concomitant medications: review for possible drug interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Interaction severity varies.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased antiviral efficacy due to reduced gastric acidity. - Methotrexate: increased serum levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring closer coagulation monitoring. - Digoxin: possible rise in serum digoxin concentrations. - Phenytoin: reduced phenytoin levels, may necessitate dose adjustment. - Ketoconazole: decreased antifungal absorption, consider alternative therapy. - Rifampin: may lower omeprazole concentrations, monitor therapeutic response.